Q1 EPS Estimates for HeartSciences Decreased by Maxim Group

HeartSciences Inc. (NASDAQ:HSCS) – Equities researchers at Maxim Group lowered their Q1 2027 EPS estimates for shares of HeartSciences in a report issued on Tuesday, July 28th. Maxim Group analyst A. Klee now expects that the company will earn ($0.83) per share for the quarter, down from their prior estimate of ($0.81). The consensus estimate for HeartSciences’ current full-year earnings is ($3.02) per share. Maxim Group also issued estimates for HeartSciences’ Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.75) EPS, Q4 2027 earnings at ($0.68) EPS, FY2027 earnings at ($2.98) EPS, Q1 2028 earnings at ($0.69) EPS, Q2 2028 earnings at ($0.64) EPS, Q3 2028 earnings at ($0.49) EPS, Q4 2028 earnings at ($0.34) EPS and FY2028 earnings at ($2.13) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

HeartSciences Price Performance

NASDAQ HSCS opened at $2.08 on Friday. The company has a market cap of $8.11 million, a price-to-earnings ratio of -0.53 and a beta of 1.78. The stock’s fifty day moving average price is $2.30 and its 200 day moving average price is $2.47. HeartSciences has a 1 year low of $1.63 and a 1 year high of $3.93.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings data on Thursday, July 23rd. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.22).

Institutional Trading of HeartSciences

An institutional investor recently bought a new stake in HeartSciences stock. Geode Capital Management LLC acquired a new stake in HeartSciences Inc. (NASDAQ:HSCS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences at the end of the most recent reporting period. Institutional investors own 17.24% of the company’s stock.

HeartSciences News Summary

Here are the key news stories impacting HeartSciences this week:

• Positive Sentiment: HeartSciences filed a preliminary proxy statement for its proposed combination with Fortitude Mining Holdings, which would give shareholders exposure to Fortitude’s Zcash mining operations. Fortitude says it mined approximately 28% of total ZEC production in the six months ended June 30 and expects its expanded infrastructure to reduce mining costs. HeartSciences Files Preliminary Proxy Statement and Reports Fiscal 2026 Results
• Positive Sentiment: Fortitude purchased 9,000 Bitmain Antminer Z15 Pro units, signaling continued investment in Zcash mining capacity and potentially strengthening the strategic rationale for the proposed transaction. Fortitude Purchases 9,000 Bitmain Antminer Z15 Pro Units
• Positive Sentiment: Maxim Group improved several long-term earnings forecasts, including FY2028 EPS to a loss of $2.13 from a loss of $2.21, while raising estimates for the first three quarters of 2028. The revisions suggest expectations for gradually narrowing losses.
• Neutral Sentiment: HeartSciences reported progress in its healthcare technology business, including the commercial launch of the MyoVista Insights platform, institutional deployments and an FDA review of the MyoVista wavECG device.
• Negative Sentiment: The company reported no meaningful fiscal 2026 revenue and had approximately $1.7 million in cash and only $0.2 million of shareholders’ equity, highlighting substantial funding and execution risk.
• Negative Sentiment: The proposed transaction remains subject to shareholder and regulatory approvals and includes authorization for a potential 1-for-2 to 1-for-5 reverse stock split to maintain Nasdaq compliance. The split and listing deficiencies may weigh on sentiment because they could reduce share liquidity and signal financial weakness.
• Negative Sentiment: Maxim lowered several near-term forecasts, including FY2027 EPS to a loss of $2.98 from a loss of $2.93 and Q1 2027 EPS to a loss of $0.83 from a loss of $0.81. HeartSciences also recently missed its quarterly EPS consensus estimate, reinforcing concerns about continuing losses.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.